In yesterday’s Wall Street session, Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares traded at $11.40, up 2.24% from the previous session.
16 analysts cover Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $10.00, we find $14.50. Given the previous closing price of $11.15, this indicates a potential upside of 30.04 percent. ICPT stock price is now -9.19% away from the 50-day moving average and -24.08% away from the 200-day moving average. The market capitalization of the company currently stands at $481.08M.
The stock has received a hold rating from 9 analysts and a buy rating from 4. Brokers who have rated the stock have averaged $15.25 as their price target over the next twelve months.
With the price target enhanced from $8 to $19, H.C. Wainwright Upgraded its rating from Sell to Buy for Intercept Pharmaceuticals Inc. (NASDAQ: ICPT).
Insiders disposed of 24,566 shares of company stock worth roughly $0.28 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ICPT stock. A new stake in Intercept Pharmaceuticals Inc. shares was purchased by ADAGE CAPITAL PARTNERS GP, L.L.C. during the first quarter worth $4,998,000. PRUDENTIAL FINANCIAL INC invested $2,569,000 in shares of ICPT during the first quarter. In the first quarter, MARSHALL WACE, LLP acquired a new stake in Intercept Pharmaceuticals Inc. valued at approximately $1,292,000. JANE STREET GROUP, LLC acquired a new stake in ICPT for approximately $992,000. PROFUND ADVISORS LLC purchased a new stake in ICPT valued at around $545,000 in the second quarter. In total, there are 228 active investors with 80.60% ownership of the company’s stock.
On Thursday morning Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) stock kicked off with the opening price of $12.00. During the past 12 months, Intercept Pharmaceuticals Inc. has had a low of $8.82 and a high of $21.86. As of last week, the company has a debt-to-equity ratio of 4.96, a current ratio of 2.40, and a quick ratio of 2.40. The fifty day moving average price for ICPT is $12.36 and a two-hundred day moving average price translates $14.99 for the stock.
The latest earnings results from Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.77, missing analysts’ expectations of -$0.65 by -0.12. This compares to $0.54 EPS in the same period last year. The net profit margin was 70.30% and return on equity was -812.50% for ICPT. The company reported revenue of $67.96 million for the quarter, compared to $59.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.9 percent. For the current quarter, analysts expect ICPT to generate $79.31M in revenue.
Intercept Pharmaceuticals Inc.(ICPT) Company Profile
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.
